Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Biogen (BGEN) fell $12 (18 percent) to $53 on Tuesday. After
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury